WuXi Biologics is trading 8.56% up now at HK$52.00 after biotechnology shares rallied broadly on positive mRNA cancer-vaccine trial results from Moderna and Merck.
- The sector catalyst appears more likely than a fresh company-specific announcement.
- WuXi Biologics’ recent divestment of Bestchrom was announced August 14, while its next interim-results board meeting is scheduled for August 25, so neither directly explains August 20’s move.